196 related articles for article (PubMed ID: 32806028)
21. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Vishwanatha JK; Mathew PA
Am J Cancer Res; 2018; 8(6):1050-1063. PubMed ID: 30034942
[TBL] [Abstract][Full Text] [Related]
22. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
23. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
24. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
25. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
26. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
27. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
Nam JS; Terabe M; Mamura M; Kang MJ; Chae H; Stuelten C; Kohn E; Tang B; Sabzevari H; Anver MR; Lawrence S; Danielpour D; Lonning S; Berzofsky JA; Wakefield LM
Cancer Res; 2008 May; 68(10):3835-43. PubMed ID: 18483268
[TBL] [Abstract][Full Text] [Related]
28. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
29. Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells.
Choi SH; Cho HB; Choi JH; Kim HJ; Jang HJ; Cho S; Maeng E; Park H; Ryu KS; Park KH; Park KS
J Control Release; 2024 Mar; 367():768-778. PubMed ID: 38341178
[TBL] [Abstract][Full Text] [Related]
30. CD56 regulates human NK cell cytotoxicity through Pyk2.
Gunesch JT; Dixon AL; Ebrahim TA; Berrien-Elliott MM; Tatineni S; Kumar T; Hegewisch-Solloa E; Fehniger TA; Mace EM
Elife; 2020 Jun; 9():. PubMed ID: 32510326
[TBL] [Abstract][Full Text] [Related]
31. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
32. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.
Powell AB; Yadavilli S; Saunders D; Van Pelt S; Chorvinsky E; Burga RA; Albihani S; Hanley PJ; Xu Z; Pei Y; Yvon ES; Hwang EI; Bollard CM; Nazarian J; Cruz CRY
J Transl Med; 2019 Sep; 17(1):321. PubMed ID: 31547819
[TBL] [Abstract][Full Text] [Related]
33. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
34. Novaferon gene modification promotes NK92 cell anti-tumor activity.
Zhang W; Yu B; Meng Q; Pu L; Liu B; Li F
Int Immunopharmacol; 2023 Sep; 122():110613. PubMed ID: 37421776
[TBL] [Abstract][Full Text] [Related]
35. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
36. Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics.
Market M; Tennakoon G; Scaffidi M; Cook DP; Angka L; Ng J; Tanese de Souza C; Kennedy MA; Vanderhyden BC; Auer RC
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498937
[TBL] [Abstract][Full Text] [Related]
37. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
38. Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms.
Du Y; Liu X; Guo SW
Hum Reprod; 2017 Apr; 32(4):794-810. PubMed ID: 28184445
[TBL] [Abstract][Full Text] [Related]
39. Role of NKG2D and its ligands in cancer immunotherapy.
Liu H; Wang S; Xin J; Wang J; Yao C; Zhang Z
Am J Cancer Res; 2019; 9(10):2064-2078. PubMed ID: 31720075
[TBL] [Abstract][Full Text] [Related]
40. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
